Cargando…

[(18)F]FDG-6-P as a novel in vivo tool for imaging staphylococcal infections

BACKGROUND: Management of infection is a major clinical problem. Staphylococcus aureus is a Gram-positive bacterium which colonises approximately one third of the adult human population. Staphylococcal infections can be life-threatening and are frequently complicated by multi-antibiotic resistant st...

Descripción completa

Detalles Bibliográficos
Autores principales: Mills, Bethany, Awais, Ramla O, Luckett, Jeni, Turton, Dave, Williams, Paul, Perkins, Alan C, Hill, Philip J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385282/
https://www.ncbi.nlm.nih.gov/pubmed/25853019
http://dx.doi.org/10.1186/s13550-015-0095-1
_version_ 1782365038636433408
author Mills, Bethany
Awais, Ramla O
Luckett, Jeni
Turton, Dave
Williams, Paul
Perkins, Alan C
Hill, Philip J
author_facet Mills, Bethany
Awais, Ramla O
Luckett, Jeni
Turton, Dave
Williams, Paul
Perkins, Alan C
Hill, Philip J
author_sort Mills, Bethany
collection PubMed
description BACKGROUND: Management of infection is a major clinical problem. Staphylococcus aureus is a Gram-positive bacterium which colonises approximately one third of the adult human population. Staphylococcal infections can be life-threatening and are frequently complicated by multi-antibiotic resistant strains including methicillin-resistant S. aureus (MRSA). Fluorodeoxyglucose ([(18)F]FDG) imaging has been used to identify infection sites; however, it is unable to distinguish between sterile inflammation and bacterial load. We have modified [(18)F]FDG by phosphorylation, producing [(18)F]FDG-6-P to facilitate specific uptake and accumulation by S. aureus through hexose phosphate transporters, which are not present in mammalian cell membranes. This approach leads to the specific uptake of the radiopharmaceutical into the bacteria and not the sites of sterile inflammation. METHODS: [(18)F]FDG-6-P was synthesised from [(18)F]FDG. Yield, purity and stability were confirmed by RP-HPLC and iTLC. The specificity of [(18)F]FDG-6-P for the bacterial universal hexose phosphate transporter (UHPT) was confirmed with S. aureus and mammalian cell assays in vitro. Whole body biodistribution and accumulation of [(18)F]FDG-6-P at the sites of bioluminescent staphylococcal infection were established in a murine foreign body infection model. RESULTS: In vitro validation assays demonstrated that [(18)F]FDG-6-P was stable and specifically transported into S. aureus but not mammalian cells. [(18)F]FDG-6-P was elevated at the sites of S. aureus infection in vivo compared to uninfected controls; however, the increase in signal was not significant and unexpectedly, the whole-body biodistribution of [(18)F]FDG-6-P was similar to that of [(18)F]FDG. CONCLUSIONS: Despite conclusive in vitro validation, [(18)F]FDG-6-P did not behave as predicted in vivo. However at the site of known infection, [(18)F]FDG-6-P levels were elevated compared with uninfected controls, providing a higher signal-to-noise ratio. The bacterial UHPT can transport hexose phosphates other than glucose, and therefore alternative sugars may show differential biodistribution and provide a means for specific bacterial detection.
format Online
Article
Text
id pubmed-4385282
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-43852822015-04-07 [(18)F]FDG-6-P as a novel in vivo tool for imaging staphylococcal infections Mills, Bethany Awais, Ramla O Luckett, Jeni Turton, Dave Williams, Paul Perkins, Alan C Hill, Philip J EJNMMI Res Original Research BACKGROUND: Management of infection is a major clinical problem. Staphylococcus aureus is a Gram-positive bacterium which colonises approximately one third of the adult human population. Staphylococcal infections can be life-threatening and are frequently complicated by multi-antibiotic resistant strains including methicillin-resistant S. aureus (MRSA). Fluorodeoxyglucose ([(18)F]FDG) imaging has been used to identify infection sites; however, it is unable to distinguish between sterile inflammation and bacterial load. We have modified [(18)F]FDG by phosphorylation, producing [(18)F]FDG-6-P to facilitate specific uptake and accumulation by S. aureus through hexose phosphate transporters, which are not present in mammalian cell membranes. This approach leads to the specific uptake of the radiopharmaceutical into the bacteria and not the sites of sterile inflammation. METHODS: [(18)F]FDG-6-P was synthesised from [(18)F]FDG. Yield, purity and stability were confirmed by RP-HPLC and iTLC. The specificity of [(18)F]FDG-6-P for the bacterial universal hexose phosphate transporter (UHPT) was confirmed with S. aureus and mammalian cell assays in vitro. Whole body biodistribution and accumulation of [(18)F]FDG-6-P at the sites of bioluminescent staphylococcal infection were established in a murine foreign body infection model. RESULTS: In vitro validation assays demonstrated that [(18)F]FDG-6-P was stable and specifically transported into S. aureus but not mammalian cells. [(18)F]FDG-6-P was elevated at the sites of S. aureus infection in vivo compared to uninfected controls; however, the increase in signal was not significant and unexpectedly, the whole-body biodistribution of [(18)F]FDG-6-P was similar to that of [(18)F]FDG. CONCLUSIONS: Despite conclusive in vitro validation, [(18)F]FDG-6-P did not behave as predicted in vivo. However at the site of known infection, [(18)F]FDG-6-P levels were elevated compared with uninfected controls, providing a higher signal-to-noise ratio. The bacterial UHPT can transport hexose phosphates other than glucose, and therefore alternative sugars may show differential biodistribution and provide a means for specific bacterial detection. Springer Berlin Heidelberg 2015-03-19 /pmc/articles/PMC4385282/ /pubmed/25853019 http://dx.doi.org/10.1186/s13550-015-0095-1 Text en © Mills et al.; licensee Springer. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
spellingShingle Original Research
Mills, Bethany
Awais, Ramla O
Luckett, Jeni
Turton, Dave
Williams, Paul
Perkins, Alan C
Hill, Philip J
[(18)F]FDG-6-P as a novel in vivo tool for imaging staphylococcal infections
title [(18)F]FDG-6-P as a novel in vivo tool for imaging staphylococcal infections
title_full [(18)F]FDG-6-P as a novel in vivo tool for imaging staphylococcal infections
title_fullStr [(18)F]FDG-6-P as a novel in vivo tool for imaging staphylococcal infections
title_full_unstemmed [(18)F]FDG-6-P as a novel in vivo tool for imaging staphylococcal infections
title_short [(18)F]FDG-6-P as a novel in vivo tool for imaging staphylococcal infections
title_sort [(18)f]fdg-6-p as a novel in vivo tool for imaging staphylococcal infections
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385282/
https://www.ncbi.nlm.nih.gov/pubmed/25853019
http://dx.doi.org/10.1186/s13550-015-0095-1
work_keys_str_mv AT millsbethany 18ffdg6pasanovelinvivotoolforimagingstaphylococcalinfections
AT awaisramlao 18ffdg6pasanovelinvivotoolforimagingstaphylococcalinfections
AT luckettjeni 18ffdg6pasanovelinvivotoolforimagingstaphylococcalinfections
AT turtondave 18ffdg6pasanovelinvivotoolforimagingstaphylococcalinfections
AT williamspaul 18ffdg6pasanovelinvivotoolforimagingstaphylococcalinfections
AT perkinsalanc 18ffdg6pasanovelinvivotoolforimagingstaphylococcalinfections
AT hillphilipj 18ffdg6pasanovelinvivotoolforimagingstaphylococcalinfections